Cencora Earnings Call: Key Takeaways
Cencora delivered strong FY2026 results with 14% operating income growth and introduced a new reporting structure to highlight high-growth specialty services and MSO platforms.
- Call
- Nov 4, 2026, 8:30 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cencora, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
7 alerts with these filters
Cencora delivered strong FY2026 results with 14% operating income growth and introduced a new reporting structure to highlight high-growth specialty services and MSO platforms.
Cencora, Inc. announced a reorganization of its operating model and reporting structure to advance growth priorities and improve visibility. Beginning in fiscal 2027, the company will report results across three segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The filing includes supplemental unaudited historical segment data for fiscal 2025 and 2026 recast under this new structure to assist investor analysis.
Cencora reported fiscal year 2026 revenue of $337.4 billion, up 5.0% year-over-year, and adjusted diluted EPS of $17.97. The company introduced a new operating model and reportable segments following its acquisition of OneOncology and provided fiscal 2027 adjusted EPS guidance of $19.40 to $19.75.
“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.”
Robert P. Mauch, President and Chief Executive Officer of Cencora
“As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress.”
Robert P. Mauch, President and Chief Executive Officer of Cencora
Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $330.96 a share, worth $326K in total on Nov 2, 2026. Shares held after the trade: 14,197 (-6.5%).
Cencora has signed a definitive agreement to acquire American Oncology Network (AON) for an enterprise value of $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The acquisition expands Cencora's oncology management services organization (MSO) platform by adding a network of over 350 oncology providers across 21 states.
Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $303.18 a share, worth $299K in total on Oct 1, 2026. Shares held after the trade: 15,183 (-6.1%).
Cencora, Inc. appointed Robert E. Sanchez, the former Executive Chair and CEO of Ryder System, Inc., to its Board of Directors effective October 1, 2026. In connection with the appointment, the Board increased its size from ten to eleven members. Mr. Sanchez will receive standard non-employee director compensation, including a pro-rated annual equity award.